Caris Life Sciences Upsizes IPO to Raise $459 Million Amid Strong Investor Demand

Intelligent Finance APP learned on Monday that Caris Life Sciences (CAI.US), an artificial intelligence platform focused on molecular diagnostics in oncology, announced an increase in the price range for its upcoming initial public offering (IPO).

This Irving, Texas-based company plans to issue 23.5 million shares at a price of $19 to $20 per share, raising a total of $459 million. The company had previously reported a price range of $16 to $18 per share. Insiders intend to subscribe for $75 million worth of shares (16% of this offering). Based on the midpoint of the revised range, Caris Life Sciences' fundraising amount will be 15% higher than originally expected.

The company is dedicated to developing and commercializing a precision medicine diagnostic platform that integrates next-generation gene sequencing, artificial intelligence, and machine learning technologies to provide solutions for cancer treatment. Caris Life Sciences stated that its platform, based on over 6.5 million test data points from more than 849,000 clinical cases, has analyzed over 38 billion molecular markers cumulatively. The current commercial product line focuses on the oncology field, mainly including: MI Profile, a tissue molecular profiling solution (which has been the company's primary source of revenue to date), and Caris Assure, a blood molecular profiling product fully launched in the first quarter of 2024 (used for treatment selection).

Caris Life Sciences, founded in 2008, generated $452 million in revenue for the 12 months ended March 31, 2025. The company plans to list on Nasdaq under the ticker symbol "CAI." The IPO is jointly led by BofA Securities, J.P. Morgan, Goldman Sachs, Citi, TD Cowen, Evercore ISI, and Guggenheim Securities as joint book-running managers, with pricing expected to be completed in the week of June 16, 2025.